MCHRI News & Updates
Monday, December 2, 2024, 12-1pm
Online via Zoom ONLY
Suprazygomatic Maxillary Nerve Blocks and Opioid Requirements in Pediatric Adenotonsillectomy: A Randomized Clinical Trial
Description: Learn about the use of the suprazygomatic maxillary nerve block in pediatric surgery and its potential to reduce opioid use. This session will discuss the procedure’s efficacy in managing postoperative pain, its application in pediatric patients, and the clinical insights from recent trials. Discover how regional anesthesia techniques are advancing pain management strategies in pediatric care.
Speakers:
Carole Lin, MD, Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Steven Abboud, MD, Staff Anesthesiologist, Kaiser Permanente
 (6.8 x 4.9 in).png)
Friday, December 6, 2024, 12-1:30Ppm
Qualitative Research Workshop - See Full Series Here
Disseminating Qualitative Research Findings: Partner Feedback, Presenting Findings, and Translation of Findings
Description: At the end of this workshop, participants will be able to:
Identify how to take your qualitative research findings and obtain feedback from your participants or community partners
Describe different ways to present qualitative findings
Learn different ways to translate your findings to affect practices, interventions, and policies
Speakers:
Bonnie Halpern-Felsher, PhD, FSAHM, Marron and Mary Elizabeth Kendrick Professor, Pediatrics and Professor (by courtesy), Epidemiology & Population Health and Psychiatry & Behavioral Sciences; Director, Stanford REACH Lab
Kimberly Pyke-Grimm, PhD, RN, CSN, CPHON, Nurse Scientist, Nursing Research and Evidence-Based Practice; Clinical Assistant Professor, Pediatrics (Hematology/Oncology)
Stanford Medicine News
-
Newer antiseizure drugs safe for pregnancy, Stanford Medicine-led study shows
Six-year-olds who were exposed prenatally to common antiseizure medications had normal verbal and cognitive abilities, a large, multisite study has found.
-
Stanford Medicine study discovers what’s behind heart cell damage from chemotherapy
Researchers used a new screening technique to identify genes involved in heart cell damage during a common chemotherapy treatment. They also found a drug that may be able to prevent it.
-
FDA approves Stanford Medicine-developed drug that treats rare heart disease
New drug treats a rare heart disease, transthyretin amyloid cardiomyopathy, or ATTR-CM.
FUNDED PARTNERS
